BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia
() -- BioMarin Pharmaceutical (BMRN) said Monday that the US Food and Drug Administration has accepted its supplemental new drug application seeking full approval of Voxzogo to treat children with achondroplasia. The regulator has set a Prescription Drug User Fee Act target action date of Feb. 28, 2027, the company sai